In addition, sensitizing AML cells to chemotherapy by SIRT3 inhibitor may also be due to the altered unique biological function of its targets, such as IDH2.These data suggest SIRT3 and its modifiers can be exploited as therapeutic targets to ameliorate the anti‐tumour efficacy of currently used chemotherapeutic agents. Here, SIRT3 is linked to acute myeloid leukemia.